CGCI Research Results and “Live Case” Presented at EHRA Europace Conference in Madrid
Magnetecs Corporation, a designer and manufacturer of robotic catheterization control systems for minimally invasive surgical procedures, today reported that an abstract presentation of research performed under the direction of Dr. Jose Luis Merino Llorens, Director of the Arrhythmia–Electrophysiology Research Unit at Hospital Universitario La Paz in Madrid, Spain, using the Company’s robotic Catheter Guidance Control and Imaging (CGCI) system will be presented at the upcoming EHRA Europace Congress in Madrid on June 27, 2011. Dr. Merino’s presentation, “Fast reacting electromagnets for remote navigation of the mapping catheter: First results in humans,” will take place at the Valencia Lecture Room at 17:00 at the IFEMA Convention Center.
The first phase of human clinical trials for patients with arrhythmia was recently completed at La Paz Hospital. In this study, a highly detailed map of the heart was created using the CGCI system in conjunction with EnSite NavX Navigation and Visualization Technology. The primary outcome of the study measures intracardiac anatomic site target acquisition and repetition of acquisition. A description of the study can be found at ClincalTrials.gov.
LIVE CASE PRESENTATION OF CGCI AT EHRA CONGRESS IN MADRID, SPAIN
CGCI Installation, La Paz Hospital, Madrid
A “Live-Case” study of the Magnetecs CGCI system will be performed by Dr. Merino on June 28, 2011, at 14:00 at the 2011 EHRA Europace Congress.
The “Live Case” presentation will consist of a cardiac mapping procedure using the robotic CGCI system. The procedure will be simulcast to approximately 5000 cardiologists and other EHRA attendees in Madrid, Spain, Leipzig, Germany as well as select locations in the Netherlands.
“Through its groundbreaking clinical research, La Paz Hospital in Madrid is an early leader in the development of robotic procedures in the field of electrophysiology using our advanced technology for electromagnetic catheter guidance and control,” said Josh Shachar, CEO of Magnetecs Corporation. “This cornerstone installation is expected to continue proving the efficacy, safety, and operational efficiency of CGCI.”
“In addition to the research we are conducting at La Paz Hospital, we are developing protocols to conduct extensive clinical trials at Mount Sinai Medical Center in New York City and in several additional locations in the United States, Asia, Canada, and Europe,” added Dr. Eli Gang, M.D., Chief Medical Officer of Magnetecs, Clinical Professor of Medicine at the UCLA Medical School, and Director of the Clinical Electrophysiology Laboratory at Brotman Hospital in Los Angeles. “As the number of CGCI installations sites expand in accordance with our global regulatory strategy, we look forward to the commercialization of the robotic CGCI system so this technology can reach arrhythmia patients around the world,” concluded Dr. Gang.
PLANNED CGCI INSTALLATIONS
Magnetecs has completed a definitive agreement to install its CGCI system at Mount Sinai Medical Center in New York City in 2012. In Europe, the Company has completed a definitive agreement to install its CGCI system at Na Homolce Hospital in Prague, Czech Republic. Several additional installations are currently planned in the U.S., U.K., Canada, South Korea, Italy, Israel, Scandinavia, and Asia.